Panacea Biotec launches EasyFourPol® in India and receives registration of Valganciclovir Powder for Oral Solution in Germany

Panacea Biotec, one of India's leading biotechnology company announced the launch of world's first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol® , in India and registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step-down wholly-owned subsidiary company viz. Panacea Biotec Germany GmbH, in Germany.

EasyFourPol® is the world's first fully liquid wP-IPV Pentavalent vaccine. wP-IPV Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.

EasyFourPol® is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic. It achieves the same level of protection as immunized with single-antigen vaccines, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders. It leads to less vaccination and lesser shots for the child and greater comfort for the parents while ensuring better compliance for healthcare practitioners. Fewer shots also mean time saved for parents and more efficiency at points of vaccination. Additionally, it also helps reduce carbon emissions by reducing the need for vials, syringes, packaging material, and visits to vaccine administration centres.

For healthcare practitioners who follow Indian Academy of Paediatrics' (IAP) recommended Immunisation schedule, EasyFourPol® offers a credible option for booster dose. EasyFourPol® has an addressable market size of INR 51 crore in India.

Paediatric vaccination plays an important role to achieve Sustainable Development Goals (SDGs) set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births.

Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec, said, "We are delighted to launch EasyFourPol® - another landmark in our innovative and first-in-class combination vaccine portfolio that makes vaccinations easier, benefits the child, parents, and doctors while helping the world meet UN Sustainable Development Goals. We are certain that Indian paediatricians and parents will continue to put their trust in Panacea Biotec to meet evergrowing vaccination needs through innovative solutions."

Panacea Biotec Germany GmbH, a step-down wholly owned subsidiary of Panacea Biotec, is excited to announce registration of Valganciclovir 50 rng/rnl Powder for Oral Solution in Germany. It competes in a €1 million market (as per IQVIA). The medication is a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor indicated for:

- the initial and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).

- the prophylaxis of CMV disease in CMV-negative adults and children (from birth and up to 18 years of age) who have received an organ transplant from a CMV-positive donor.

Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec, further said, "In continuation of our belief to broaden our focus while continuing our therapy focus - Valganciclovir Powder for Oral Solution is a welcome addition to our transplant portfolio in Germany. We look forward to scaling up our operations and continue to build trust with healthcare practitioners as a high-quality sustainable supplier of medicines for transplant care."

Shares of Panacea Biotec Limited was last trading in BSE at Rs. 167.20 as compared to the previous close of Rs. 163.00. The total number of shares traded during the day was 39654 in over 691 trades.

The stock hit an intraday high of Rs. 177.75 and intraday low of 166.30. The net turnover during the day was Rs. 6799886.00.

Source : Equity Bulls

Keywords

PanaceaBiotec INE922B01023 EasyFourPol India Launch Registration ValganciclovirPowder OralSolutions Germany